Literature DB >> 19536515

Preliminary comments on proteasome inhibition and cardiovascular disease.

Friedrich C Luft1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19536515     DOI: 10.1007/s00109-009-0492-x

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


× No keyword cloud information.
  5 in total

1.  Targeting proteasome worsens atherosclerosis.

Authors:  Tohru Fukai
Journal:  Circ Res       Date:  2007-10-26       Impact factor: 17.367

Review 2.  Mechanisms of proteasome inhibitor action and resistance in cancer.

Authors:  David J McConkey; Keyi Zhu
Journal:  Drug Resist Updat       Date:  2008-09-24       Impact factor: 18.500

3.  Chronic proteasome inhibition contributes to coronary atherosclerosis.

Authors:  Joerg Herrmann; Ardan M Saguner; Daniele Versari; Timothy E Peterson; Alejandro Chade; Monica Olson; Lilach O Lerman; Amir Lerman
Journal:  Circ Res       Date:  2007-09-06       Impact factor: 17.367

4.  Potent anti-inflammatory effects of low-dose proteasome inhibition in the vascular system.

Authors:  Antje Ludwig; Mandy Fechner; Nicola Wilck; Silke Meiners; Nicole Grimbo; Gert Baumann; Verena Stangl; Karl Stangl
Journal:  J Mol Med (Berl)       Date:  2009-04-28       Impact factor: 4.599

5.  The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.

Authors:  Kirsten Neubert; Silke Meister; Katrin Moser; Florian Weisel; Damian Maseda; Kerstin Amann; Carsten Wiethe; Thomas H Winkler; Joachim R Kalden; Rudolf A Manz; Reinhard E Voll
Journal:  Nat Med       Date:  2008-06-08       Impact factor: 53.440

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.